Advertisement
Advertisement
U.S. Markets open in 5 hrs 28 mins
Advertisement
Advertisement
Advertisement
Advertisement

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.34-2.73 (-6.34%)
At close: 04:00PM EST
40.34 0.00 (0.00%)
After hours: 07:39PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close43.07
Open42.05
Bid0.00 x 1000
Ask0.00 x 1200
Day's Range40.31 - 43.49
52 Week Range28.40 - 55.19
Volume783,434
Avg. Volume976,363
Market Cap3.286B
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-3.20
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.44
  • GuruFocus.com

    Penbrook Management LLC Buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Sells ...

    New York, NY, based Investment company Penbrook Management LLC (Current Portfolio) buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Chevron Corp, Intra-Cellular Therapies Inc, sells Nuance Communications Inc, Aspen Group Inc, The One Group Hospitality Inc, Landmark Infrastructure Partners LP, Global Partners LP during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Penbrook Management LLC.

  • GlobeNewswire

    Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. In addition, the underwriters have exercised in full their option to purchase an additional 1,42

  • GlobeNewswire

    Intra-Cellular Therapies Prices Public Offering of Common Stock

    NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to

Advertisement
Advertisement